Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists.
about
Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in chinaSafety and immunotoxicity assessment of immunomodulatory monoclonal antibodiesPatterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study.Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now?Etanercept ameliorates inflammation and pain in a novel mono-arthritic multi-flare model of streptococcal cell wall induced arthritis.Aging impairs murine B cell differentiation and function in primary and secondary lymphoid tissuesInflammaging decreases adaptive and innate immune responses in mice and humansA molecular mechanism for TNF-α-mediated downregulation of B cell responses.Antigen-specific gene therapy after immunisation reduces the severity of collagen-induced arthritis.High TNF-α levels in resting B cells negatively correlate with their response.Senescent B cells in aging and age-related diseases: Their role in the regulation of antibody responses.Adipose Tissue Inflammation Induces B Cell Inflammation and Decreases B Cell Function in Aging.How does cytomegalovirus factor into diseases of aging and vaccine responses, and by what mechanisms?
P2860
Q28484306-C64ACBCB-A9E4-4CC2-B015-9F487620F40BQ33895804-5567549C-13B3-403B-93DE-CE727C3AA9B6Q34022346-073E27C9-776B-4583-AD35-8E932A979D60Q34338355-224E8ACD-BDC9-4148-BE49-D27ED40E026FQ35060214-971FADA2-AC91-42C3-B643-48333FFA065CQ35806803-DACB23DB-E474-48CB-B1B6-6A6C2531DB86Q36225887-3C9B531A-3684-4579-A63A-69991C3CA7F8Q36979267-59F376F0-716D-40B2-9C88-0059704F17F6Q37382486-273C907F-3A94-4FC1-AABD-B4BA10E8E8B3Q37707181-637FCE9E-4E1A-4AFD-94F7-68A24A628383Q39421902-C4D68FCE-6FD1-4FCB-AEFD-096E4F9D43F6Q48000215-B55AE6B8-F357-4F12-A153-687958685C1EQ55315794-E4252793-6D26-4CA1-8E36-16D4C77097BE
P2860
Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Therapeutic agents for patient ...... osis factor-alpha antagonists.
@en
Therapeutic agents for patient ...... osis factor-alpha antagonists.
@nl
type
label
Therapeutic agents for patient ...... osis factor-alpha antagonists.
@en
Therapeutic agents for patient ...... osis factor-alpha antagonists.
@nl
prefLabel
Therapeutic agents for patient ...... osis factor-alpha antagonists.
@en
Therapeutic agents for patient ...... osis factor-alpha antagonists.
@nl
P2860
P1476
Therapeutic agents for patient ...... osis factor-alpha antagonists.
@en
P2860
P304
P356
10.1517/14712590903379494
P407
P577
2009-12-01T00:00:00Z